Several partners have co-validated the genO-hSA/hFcRn mouse model
Key publications & posters
- CB307:A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors, Archer S, et al. (2024), Clinical Cancer Research.
- Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin, Ma G, et al. (2024), JCI Insight.
- In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders, Vantourout JC, et al. (2021), Bioconjugate Chemistry.
- Generation of a double transgenic humanised neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs, Viuff D, et al. (2015), J Control Release.
- Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1, presented by Avacta at AACR 2021.
What sets the genO-hSA/hFcRn mouse model apart?
- Physiological expression pattern and levels of expression of both hSA and hFcRn
- Serum albumin and FcRn are humanized to optimize drug binding, as murine albumin has higher affinity for hFcRn than human albumin
Create a customized model for PK and efficacy evaluation of your antibody
Thanks to 25 years of proven track record in developing custom-made models, genOway offers an in-depth analysis of projects to design a model fully adapted to your research, with strategic selection of the gene engineering technology.
Examples of models created with genO-hSA/hFcRn background
In order to expand the range of applications of our genO-hSA/hFcRn mouse, this model has been intercrossed with several other models:
- genO-hFcγR/hFcRn to improve PK/PD assessment of Fc-dependent antibodies
- genO-hTFRC/hSA/hFcRn to improve assessment of compounds crossing the blood-brain barrier
- genO-hSA/hFcRn/hIgG1 for an increased tolerance to human hIgG1
Create a custom-made model for PK Profiling with genO-hSA/hFcRn
Get in touch about
Let us know how we can help
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe